Gender-related Therapeutical Response to Apremilast: New Insights in a Tailored Management of Psoriasis
Keywords:
psoriasis, small-molecule, obesity, weight, BMIAbstract
Introduction: Psoriasis is a chronic immune-mediated skin condition. One of the intriguing challenges in studying psoriasis has been identification of correlations between this disease and gender and body weight.
Objective: A multicenter retrospective study was conducted among patients with moderate-to-severe psoriasis who attended the outpatient clinics of 6 University Hospitals in Italy. The effects of apremilast on weight and body mass index (BMI) according to gender after 24 weeks and 48 weeks of therapy were considered.
Methods: We enrolled retrospectively 120 adult patients with moderate-to-severe psoriasis who underwent apremilast treatment for at least 24 weeks. Baseline characteristics, including age, gender, psoriasis area severity index (PASI), comorbidities, smoking and alcohol habits, relevant medical history and previous psoriasis systemic and biologic treatments were recorded. Weight and body mass index (BMI) were evaluated at baseline (T0) and at 24 (w24) and 48 weeks (w48). A descriptive statistical analysis has been performed.
Results: The analysis showed a significant reduction in body weight in females at w24 and w48 (p < 0.001), with a mean difference of −2.6 kg at w24 and of -5.7 kg at w48. We observed a reduction of weight of 3.6% at w24, and 7.9% at w48. Similar assessments were also observed for BMI, which was reduced in women by 3.6% at w24 and 8% at w48. In men, no changes in weight and BMI were observed at w24 and/or w48.
Conclusion: Understanding the interplay between psoriasis, gender, and body weight is essential for effective disease management and improving patient outcomes.
References
Mustansir Sahi F, Masood A, Danawar NA, Mekaiel A, Haider Malik B. Association Between Psoriasis and Depression: A Traditional Review. Cureus 2020 Aug 13;12(8):e9708. PMID: 32944430 PMCID: PMC7489316 DOI: 10.7759/cureus.9708
Blackstone B, Patel R, Bewley A. Assessing and Improving Psychological Well-Being in Psoriasis: Considerations for the Clinician. Psoriasis (Auckland, N.Z.) 12 (2022): 25–33. PMID: 35371967 PMCID: PMC8965012 DOI: 10.2147/PTT.S328447
Zafiriou E, Karampinis E, Roussaki-Schulze AV. Psoriasis and Exposome: Unveiling the Inner and the External Contributors of Psoriasis Disease. Psoriasis - Recent Advances in Diagnosis and Treatment, a c. di Pierre Vereecken (IntechOpen, 2024), https://doi.org/10.5772/intechopen.1003889.
Guillet C, Seeli C, Nina M, Maul LV, Maul JT. The Impact of Gender and Sex in Psoriasis: What to Be Aware of When Treating Women with Psoriasis. Int J Womens Dermatol. 2022 Apr 13;8(2):e010. PMID: 35619672 PMCID: PMC9112394 DOI: 10.1097/JW9.0000000000000010
De Simone C, Calabrese L, Balato A, et al. Psoriasis and Its Management in Women of Childbearing Age: Tools to Increase Awareness in Dermatologists and Patients. Ital J Dermatol Venereol. 2020 Aug;155(4):434-440. PMID: 33050681 DOI: 10.23736/S0392-0488.20.06748-6
Hägg D, Sundström A, Eriksson M, Schmitt-Egenolf M. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients. Am J Clin Dermatol. 2017 Aug;18(4):583-590. PMID: 28342016 PMCID: PMC5506504 DOI: 10.1007/s40257-017-0274-0
Gottlieb AB, Ryan C, Murase JE. Clinical Considerations for the Management of Psoriasis in Women. Int J Womens Dermatol. 2019 Apr 10;5(3):141-150. PMID: 31360745 PMCID: PMC6637092 DOI: 10.1016/j.ijwd.2019.04.021
Adachi A, Honda T. Regulatory Roles of Estrogens in Psoriasis.
J Clin Med. 2022 Aug 20;11(16):4890. PMID: 36013129 PMCID: PMC9409683 DOI: 10.3390/jcm11164890.
Barros G, Duran P, Vera I, Bermúdez V. Exploring the Links between Obesity and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2022 Jul 6;23(14):7499. PMID: 35886846 PMCID: PMC9321445 DOI: 10.3390/ijms23147499
Trovato E, Rubegni P, Prignano F. Place in Therapy of Anti-IL-17 and 23 in Psoriasis According to the Severity of Comorbidities: A Focus on Cardiovascular Disease and Metabolic Syndrome. Expert Opin Biol Ther. 2022 Dec;22(12):1443-1448. PMID: 35726639 DOI: 10.1080/14712598.2022.2093106
Vata D, Tarcau BM, Popescu IA, et al. Update on Obesity in Psoriasis Patients. Life (Basel). 2023 Sep 22;13(10):1947. PMID: 37895330 PMCID: PMC10608303 DOI: 10.3390/life13101947
Duchnik E, Kruk J, Tuchowska A, Marchlewicz M. The Impact of Diet and Physical Activity on Psoriasis: A Narrative Review of the Current Evidence. Nutrients. 2023 Feb 7;15(4):840. PMID: 36839198 PMCID: PMC9958594 DOI: 10.3390/nu15040840
Hao Y, Zhu YJ, Zou S, QX et al. Metabolic Syndrome and Psoriasis: Mechanisms and Future Directions. Front Immunol. 2021 Jul 23:12:711060. PMID: 34367173 PMCID: PMC8343100 DOI: 10.3389/fimmu.2021.711060
Manzo Margiotta F, Michelucci A, Capalbo E, et al. Efficacy of Risankizumab after Intra-Class Switching between Anti IL-23 Antagonists: A Multi-Center, Retrospective, Real-Life Observation. Ital J Dermatol Venereol. 2024 Feb;159(1):64-65. PMID: 37997317 DOI: 10.23736/S2784-8671.23.07648-X
Prignano F, Pescitelli L, Trovato E, et al. Tuscany Consensus for the Treatment of Moderate-Severe Psoriasis: Update and Focus on Practical Guidelines for Place in Therapy of Anti-IL-17 and Anti-IL-23 Biologics. Ital J Dermatol Venereol. 2022 Dec;157(6):469-479. PMID: 35785927 DOI: 10.23736/S2784-8671.22.07355-8
Gooderham M, Papp KA. Apremilast in the Treatment of Psoriasis and Psoriatic Arthritis. Skin Therapy Letter. 2015 Sep-Oct;20(5):1-6. PMID: 26382906
Guerra P, Di Cesare A, Rosi E, et al. Effects on Lipid Profile after One Year of Apremilast Therapy in Patients with Psoriasis: A Monocentric Experience. Life (Basel). 2024 Mar 16;14(3):395. PMID: 38541719 PMCID: PMC10971498 DOI: 10.3390/life14030395
Ferguson LD, Cathcart S, Rimmer D, et al. Effect of the Phosphodiesterase 4 Inhibitor Apremilast on Cardiometabolic Outcomes in Psoriatic Disease-Results of the Immune Metabolic Associations in Psoriatic Arthritis Study. Rheumatology. 2022 Mar 2;61(3):1026-1034. PMID: 34097014 PMCID: PMC8889283 DOI: 10.1093/rheumatology/keab474
Kosmas CE, Rodriguez Polanco S, Bousvarou MD, et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease. Diagnostics (Basel). 2023 Mar 1;13(5):929. PMID: 36900073 PMCID: PMC10001260 DOI: 10.3390/diagnostics13050929
Crowley J, Diamant D, Joly P, et al. Long-Term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for ≥156 Weeks from 2 Phase 3, Randomized, Controlled Trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017 Aug;77(2):310-317.e1. PMID: 28416342 DOI: 10.1016/j.jaad.2017.01.052
Shah BJ, Mistry D, Chaudhary N, Shah A. Real-World Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-Severe Psoriasis. Indian Dermatol Online J. 2020 Jan 13;11(1):51-57. PMID: 32055509 PMCID: PMC7001393 DOI: 10.4103/idoj.IDOJ_169_19
Abraham TM, Pedley A, Massaro JM, Hoffmann U, Fox CS. Association between Visceral and Subcutaneous Adipose Depots and Incident Cardiovascular Disease Risk Factors. Circulation. 2015 Oct 27;132(17):1639-47. PMID: 26294660 PMCID: PMC4779497 DOI: 10.1161/CIRCULATIONAHA.114.015000
Kawai T, Autieri MV, Scalia R. Adipose Tissue Inflammation and Metabolic Dysfunction in Obesity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391. PMID: 33356944 PMCID: PMC8294624 DOI: 10.1152/ajpcell.00379.2020
Gelfand JM, Shin DB, Armstrong AW, et al. Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-Label, Nonrandomized Clinical Trial2. JAMA Dermatology. 2022 Dec 1;158(12):1394-1403. PMID: 36129688 PMCID: PMC9494263 DOI: 10.1001/jamadermatol.2022.3862
Jensen P, Christensen R, Zachariae C, et al. Long-Term Effects of Weight Reduction on the Severity of Psoriasis in a Cohort Derived from a Randomized Trial: A Prospective Observational Follow-up Study. Am J Clin Nutr. 2016 Aug;104(2):259-65. PMID: 27334236 DOI: 10.3945/ajcn.115.125849
Powell-Wiley TF, Poirier P, Burke LE, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021 May 25;143(21):e984-e1010. PMID: 33882682 PMCID: PMC8493650 DOI: 10.1161/CIR.0000000000000973
Li Q, Patrick MT, Sreeskandarajan S, Kang J, Kahlenberg JM, Gudjonsson JE. Large-Scale Epidemiological Analysis of Common Skin Diseases to Identify Shared and Unique Comorbidities and Demographic Factors. Front Immunol. 2024 Jan 8:14:1309549. PMID: 38259463 PMCID: PMC10800546 DOI: 10.3389/fimmu.2023.1309549
Hernández-Fernández CP, Carretero G, et al. Effect of Sex in Systemic Psoriasis Therapy: Differences in Prescription, Effectiveness and Safety in the BIOBADADERM Prospective Cohort. Acta Derm Venereol. 2021 Jan 4;101(1):adv00354. PMID: 33269405 PMCID: PMC9309850 DOI: 10.2340/00015555-3711
Kuryłowicz A. Estrogens in Adipose Tissue Physiology and Obesity-Related Dysfunction. Biomedicines. 2023 Feb 24;11(3):690. PMID: 36979669 PMCID: PMC10045924 DOI: 10.3390/biomedicines11030690
Wajchenberg BL. Subcutaneous and Visceral Adipose Tissue: Their Relation to the Metabolic Syndrome. Endocr Rev. 2000 Dec;21(6):697-738. PMID: 11133069 DOI: 10.1210/edrv.21.6.0415
Garenc C, Pérusse L, Chagnon YC, Rankinen T, Gagnon J, Borecki IB, et al. The Alpha2-Adrenergic Receptor Gene and Body Fat Content and Distribution: The HERITAGE Family Study. Mol Med. 2002 Feb;8(2):88-94. PMID: 12080184 PMCID: PMC2039973
Lönnqvist F, Thörne A, Large V, Arner P. Sex Differences in Visceral Fat Lipolysis and Metabolic Complications of Obesity. Arterioscler Thromb Vasc Biol. 1997 Jul;17(7):1472-80. PMID: 9261282 DOI: 10.1161/01.atv.17.7.1472
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Emanuele Trovato, Federico Bardazzi, Vito Di Lernia, Monica Corazza, Claudia Lasagni, Francesca Prignano

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.